TC BioPharm Granted European Patent for Modified Gamma Delta Cells in Cancer and Viral Treatments

EDINBURGH, Scotland, Aug. 28, 2024 -- TC BioPharm (Holdings) PLC, a clinical-stage biotechnology firm listed on NASDAQ under the ticker TCBP, has announced a significant milestone in its development of novel allogeneic gamma-delta T cell therapies aimed at treating cancer and other diseases. The European Patent Office (EPO) has granted the company a patent for the use of modified gamma delta cells in the treatment of cancer and viral conditions.

TC BioPharm plans to advance the patent process within selected European nations, aligning with their commercial strategy. "We are delighted to broaden our patent portfolio with this approval for Modified Gamma Delta T cells," stated Bryan Kobel, CEO of TC BioPharm. The company remains focused on the immediate applications of TCB008 while also working on future gamma-delta assets for conditions like solid tumors. According to Kobel, modified gamma delta T cells have the potential to surpass current CAR and modified T-cells in terms of safety and efficacy. Protecting these approaches with patents gives the company a competitive edge and enhances its value in potential acquisition scenarios.

TC BioPharm is a biopharmaceutical company engaged in the clinical-stage research, development, and commercialization of gamma-delta T cell therapies aimed at cancer treatment. These gamma-delta T cells are unique immune cells that combine properties of the innate and adaptive immune systems, allowing them to distinguish between healthy and diseased tissues. TC BioPharm is a pioneer in developing gamma-delta T cell therapies and is the first company to conduct Phase II/pivotal clinical studies in oncology for such treatments.

The company is currently conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line. One of these is a Phase 2b/3 pivotal trial focused on treating acute myeloid leukemia. This trial utilizes the company’s proprietary CryoTC technology, which provides frozen T cell products to clinics around the world, aiming to demonstrate the clinical efficacy of gamma-delta T cell therapies.

TC BioPharm’s innovative approach and recent patent approval position it at the forefront of cancer treatment research. The company's focus on gamma-delta T cells leverages their natural ability to target and attack cancerous cells while sparing healthy ones, potentially offering a new and effective therapeutic option for patients. The patent granted by the EPO not only solidifies TC BioPharm's intellectual property portfolio but also strengthens its strategic position in the highly competitive field of cancer immunotherapy.

In summary, TC BioPharm's recent patent grant marks a crucial step in the company's mission to develop and commercialize groundbreaking gamma-delta T cell therapies. By progressing with their patent strategy in Europe and continuing their clinical trials, TC BioPharm aims to provide innovative and effective treatments for cancer patients, further establishing their leadership in the field of oncology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!